(Rac)-Rotigotine hydrochloride is a dopamine receptor agonist with high affinity for D3 (Ki = 0.71 nM), D2 (Ki = 13.5 nM), D4 (Ki = 3.9–15 nM), D5 (Ki = 5.4 nM), and D1 receptors (Ki = 83 nM); it also acts as a partial agonist at the 5-HT1A receptor (Ki = 30 nM) and an antagonist at the α2B-adrenergic receptor. It exhibits 10-fold selectivity for D3 over D2, D4, and D5 receptors and 100-fold selectivity over D1 receptors. Functionally, it acts as a full agonist at all dopamine receptors, with comparable potency for D1, D2, and D3 receptor stimulation (pEC50: 9.0, 8.6–9.4, and 9.7, respectively). In primary mesencephalic cell cultures, Rotigotine (10 µM) reduces the number of tyrosine hydroxylase-immunoreactive (THir) neurons by 40%. At 0.01 µM, it provides slight protection against MPP+-induced toxicity and significant protection against rotenone-induced dopaminergic neuron death, along with marked inhibition of rotenone-induced reactive oxygen species (ROS) production.